
Smith & Nephew has left behind a difficult first half of the year characterized by supply chain issues, which have led to disappointing results for the firm.
Moreover, continued high inflation -- meaning higher costs for the British medtech firm -- and ongoing supply issues have forced Smith & Nephew to downgrade its full-year expectation of an operating margin of ”around 17.5%.”
Already a subscriber? Log in.
Read the whole article
Get access for 14 days for free.
No credit card is needed, and you will not be automatically signed up for a paid subscription after the free trial.
- Access all locked articles
- Receive our daily newsletters
- Access our app